Pharmaceutical companies have now been fully marketized, which makes the profit margins of cheap drugs, life-saving drugs are very difficult to get the favor of production enterprises, coupled with a unified bidding process around the world, the producers of the price pressure is very strong, so that the intermediate profits have been squeezed in the context of a sustained decline in the level of profitability of the objective background, whether it is raw material drug companies or production companies, will coincidentally stop these low profit margins The production of drugs, if this market model can not be changed, cheap drugs and life-saving drugs frequently cut off the supply and disappearance of the status quo can not be cracked, and even with the passage of time and increasingly serious, after all, the price of raw materials and drugs floating trend is very obvious, which led to the production of drugs at both ends of the enterprise blocked in the case of drug margins can not be improved, can only gradually reduce the output until the complete cessation of production, even if consumers have a rigid demand for these drugs, the enterprise also has a rigid demand for these drugs, the enterprise also has a rigid demand for these drugs. Even if consumers have a rigid demand for these medicines, enterprises can only choose to withdraw from the production sequence because of market pressure.
While in recent years the pharmaceutical kickbacks to maintain a high-pressure crackdown, but in the actual medical work, similar phenomena are still prevalent, and cheap drugs are not operating in this area of space, which also leads to the doctor of the type of drugs do not have the motivation to prescribe, even if the hospital pharmacy has stock, but also because there is no prescription and can not provide to the patient, which is cheap life-saving drugs are frequently cut off the supply of objective background. This is also the objective background of the frequent shortage of cheap life-saving drugs. Drug sales and medical institutions and the enthusiasm of doctors is closely related, only doctors have the subjective initiative to prescribe cheap life-saving drugs, in order to increase market sales to a certain extent, the production of drug manufacturers can be fully mobilized enthusiasm, but unfortunately, this phenomenon can not be achieved in the real world, and the health sector's supervision is not effective, but also lead to similar phenomena can not be any improvement. improvement.
Let the drug manufacturers profitable, in order to let the cheap life-saving drugs back to the medical institutions of the supply system, but only by the enterprise's self-adjustment can not be realized, drug supervision, health, medical institutions and many other departments of the establishment of a sound linkage mechanism, in order to improve the drug manufacturers to play a positive role in the business environment. In addition, the impact of the production of raw materials on the market regulation is not to be ignored, if the production of drugs upstream enterprises can not provide a reasonable price of supply of raw materials, drug manufacturers are also unable to meet the market demand, so that all aspects of the conditions have gradually matured to ensure that the market supply of cheap life-saving drugs to return to normal.